Last month, Todd Hagopian named Clovis Oncology as 1 of 3 takeover candidates. Today CLVS is trading around $76, up more than 10% on double its' normal daily volume making it the third largest position in Todd's Biotech fund.
from Forbes Real Time https://www.forbes.com/sites/kenkam/2017/09/18/clovis-up-10-on-double-normal-volume/
via IFTTT
No comments:
Post a Comment